Gonadotropin-releasing hormone antagonist (linzagolix): a new therapy for uterine adenomyosis

Condition tags

MeSH descriptors

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (45)

• Adenomyosis: a systematic review of medical treatment via openalex
• A new concept of endometriosis and adenomyosis: tissue injury and repair (TIAR) via openalex
• Combined therapeutic effects of HIFU, GnRH-a and LNG-IUS for the treatment of severe adenomyosis via openalex
• Diagnosing adenomyosis: an integrated clinical and imaging approach via openalex
• Dysmenorrhea and its severity are associated with increased uterine contractility and overexpression of oxytocin receptor (OTR) in women with symptomatic adenomyosis via openalex
• Endometriosis and the estrogen threshold theory. Relation to surgical and medical treatment. via openalex
• Gonadotrophin‐releasing hormone agonist combined with high‐intensity focused ultrasound ablation for adenomyosis: a clinical study via openalex
• Influence of adenomyosis on pregnancy and perinatal outcomes in women with endometriosis via openalex
• Introduction via openalex
• Is adenomyosis associated with menorrhagia? via openalex
• Long-term pituitary downregulation before frozen embryo transfer could improve pregnancy outcomes in women with adenomyosis via openalex
• Partial suppression of estradiol: a new strategy in endometriosis management? via openalex
• Pathogenesis of uterine adenomyosis: invagination or metaplasia? via openalex
• Peritoneal endometriosis, ovarian endometriosis, and adenomyotic nodules of the rectovaginal septum are three different entities via openalex
• Persistence of dysmenorrhea and nonmenstrual pain after optimal endometriosis surgery may indicate adenomyosis via openalex
• Pregnancy rate in women with adenomyosis undergoing fresh or frozen embryo transfer cycles following gonadotropin-releasing hormone agonist treatment via openalex
• Relationship between the magnetic resonance imaging appearance of adenomyosis and endometriosis phenotypes via openalex
• Role of transvaginal sonography and magnetic resonance imaging in the diagnosis of uterine adenomyosis via openalex
• Symptoms and classification of uterine adenomyosis, including the place of hysteroscopy in diagnosis via openalex
• The elusive adenomyosis of the uterus—revisited via openalex
• The Investigation and Management of Adenomyosis in Women Who Wish to Improve or Preserve Fertility via openalex
• The pathophysiology of endometriosis and adenomyosis: tissue injury and repair via openalex
• Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist via openalex
• Ulipristal acetate therapy increases ultrasound features of adenomyosis: a good treatment given in an erroneous diagnosis of uterine fibroids via openalex
• Uterine adenomyosis and in vitro fertilization outcome: a systematic review and meta-analysis via openalex
• Uterine adenomyosis in the infertility clinic via openalex
• What if deep endometriotic nodules and uterine adenomyosis were actually two forms of the same disease? via openalex
• W2790094279 via openalex
• W2026392453 via openalex
• W1996100965 via openalex
• W1984592479 via openalex
• W2914196959 via openalex
• W2922267617 via openalex
• W1969068003 via openalex
• W3002354512 via openalex
• W1947692703 via openalex
• W6748831126 via openalex
• W2496662864 via openalex
• W6760780416 via openalex
• W2515052691 via openalex
• W2156957181 via openalex
• W2529996311 via openalex
• W2591950961 via openalex
• W2114428497 via openalex
• W2106587450 via openalex

Cited by (38)

• The interaction between inflammation and estrogen in adenomyosis : from molecular mechanisms to therapeutic strategies 2026
• Efficacy and safety of relugolix combination therapy in women with uterine fibroids and adenomyosis: subgroup analysis of LIBERTY 1 and LIBERTY 2 2025
• Bleeding vs Thrombosis: Treatment Strategy for Women Having Large Uterine Fibroids and DVT 2024
• FEATURES OF DOPPLER INDICATORS OF UTERINE BLOOD FLOW IN PATIENTS WITH ADENOMYOSIS 2024
• The oral GnRH antagonists, a new class of drugs in gynecology: from pharmacokinetics to possible clinical applications 2024
• Shared Pathogenic and Therapeutic Characteristics of Endometriosis, Adenomyosis, and Endometrial Cancer: A Comprehensive Literature Review 2024
• Medical treatment of adenomyosis: a literature review 2023
• A method for isolating and culturing ectopic epithelial and stromal cells to study human adenomyosis 2023
• FREQUENCY AND CLINICAL AND ANAMNESTIC FEATURES OF PATIENTS WITH ADENOMYOSIS 2023
• Low-dose letrozole - an effective option for women with symptomatic adenomyosis awaiting IVF: a pilot randomized controlled trial 2023
• Changes in adenomyosis following elagolix vs leuprolide treatment in a patient with pelvic pain and infertility: A case report 2023
• The Present and the Future of Medical Therapies for Adenomyosis: A Narrative Review 2023
• Guideline No. 437: Diagnosis and Management of Adenomyosis 2023
• Evolution of uterine adenomyosis volume during and after GnRH antagonist (linzagolix) treatment: lessons for further clinical trials 2023
• Endometriosis and adenomyosis: Similarities and differences 2023
• A method for isolating and culturing ectopic epithelial and stromal cells to study human adenomyosis 2023
• The Asian Society of Endometriosis and Adenomyosis guidelines for managing adenomyosis 2023
• Rapid reduction of adenomyosis coexisting with leiomyoma volume during treatment with Relugolix 2023
• [Directive clinique no 437 : Diagnostic et prise en charge de l'adénomyose] 2023
• Adenomyosis in Reproductive Years: Abnormal Uterine Bleeding and Pain 2022
• Nonsurgical management of adenomyosis: an overview of current evidence 2022
• Medical Treatment of Adenomyosis 2022
• A Validated Model for Individualized Prediction of Live Birth in Patients With Adenomyosis Undergoing Frozen-Thawed Embryo Transfer 2022
• Conservative surgical and drug therapies for adenomyosis Medicine 2022
• Gynecological uses of GnRH antagonists: review article 2022
• Uterine Adenomyosis: From Disease Pathogenesis to a New Medical Approach Using GnRH Antagonists 2021
• A Validated Model for Individualized Prediction of Live Birth in Patients With Adenomyosis Undergoing Frozen-Thawed Embryo Transfer 2021
• A case of adenomyosis with leiomyoma that was effectively treated with relugolix and kamishoyosan add-on therapy 2021
• Endometriosis and Medical Therapy: From Progestogens to Progesterone Resistance to GnRH Antagonists: A Review 2021
• Adenomyosis: Impact on Fertility and Obstetric Outcomes 2021
• Current and Prospective Treatment of Adenomyosis 2021
• Adenomyosis and in vitro fertilization impacts - A literature review 2021
• Uterine Adenomyosis Treated by Linzagolix, an Oral Gonadotropin-Releasing Hormone Receptor Antagonist: A Pilot Study with a New ’Hit Hard First and then Maintain’ Regimen of Administration 2021
• Identifying Common Pathogenic Features in Deep Endometriotic Nodules and Uterine Adenomyosis 2021
• Progression of adenomyosis magnetic resonance imaging features under ulipristal acetate for symptomatic fibroids 2020
• Gonadotropin-releasing hormone antagonist linzagolix: possible treatment for assisted reproduction patients presenting with adenomyosis and endometriosis? 2020
• Current and Future Medical Therapies for Adenomyosis 2020
• Linzagolix: eine neue Therapieoption bei Adenomyosis uteri 2020

Source provenance

europepmc

last seen: 2026-06-13T06:22:48.782012+00:00

openalex

last seen: 2026-06-10T17:14:06.276822+00:00

pubmed

last seen: 2026-05-13T22:21:59.141895+00:00